1-naphthyl isothiocyanate increases expression ISO RGD:1595867 6480464 1-Naphthylisothiocyanate results in increased expression of RT1-BA mRNA CTD PMID:25380136 2,2',4,4',5,5'-hexachlorobiphenyl affects expression EXP 6480464 2 more ... CTD PMID:20638727 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1619269 6480464 [2 more ... CTD PMID:25510870 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1619269 6480464 [2 more ... CTD PMID:25510870 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1595867 6480464 Tetrachlorodibenzodioxin results in increased expression of RT1-BA mRNA CTD PMID:22808131 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1619269 6480464 Tetrachlorodibenzodioxin results in decreased expression of H2-AA mRNA CTD PMID:26377647 , PMID:28213091 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1619269 6480464 Tetrachlorodibenzodioxin results in increased expression of H2-AA mRNA CTD PMID:16960034 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1619269 6480464 Tetrachlorodibenzodioxin affects the expression of H2-AA mRNA CTD PMID:18343893 , PMID:28922406 2,3,7,8-Tetrachlorodibenzofuran affects expression ISO RGD:1619269 6480464 2 more ... CTD PMID:18343893 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:1619269 6480464 Trinitrobenzenesulfonic Acid results in increased expression of H2-AA mRNA CTD PMID:17982090 2,4-dinitrobenzenesulfonic acid decreases expression ISO RGD:1619269 6480464 2, 4-dinitrobenzenesulfonic acid results in decreased expression of H2-AA mRNA CTD PMID:30116771 2-butoxyethanol decreases expression ISO RGD:1619269 6480464 n-butoxyethanol results in decreased expression of H2-AA mRNA CTD PMID:19812364 3,4-methylenedioxymethamphetamine increases expression ISO RGD:1619269 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of H2-AA mRNA CTD PMID:26251327 3,4-methylenedioxymethamphetamine increases methylation ISO RGD:1619269 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased methylation of H2-AA promoter CTD PMID:26251327 3,7-dihydropurine-6-thione affects response to substance EXP 6480464 HLA-DQA1 gene polymorphism affects the susceptibility to Mercaptopurine CTD PMID:25217962 3H-1,2-dithiole-3-thione decreases expression ISO RGD:1595867 6480464 1, 2-dithiol-3-thione results in decreased expression of RT1-BA mRNA CTD PMID:19162173 4,4'-diaminodiphenylmethane increases expression ISO RGD:1595867 6480464 4, 4'-diaminodiphenylmethane results in increased expression of RT1-BA mRNA CTD PMID:25380136 4,4'-diaminodiphenylmethane decreases expression ISO RGD:1619269 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of H2-AA mRNA CTD PMID:18648102 acetamide increases expression ISO RGD:1595867 6480464 acetamide results in increased expression of RT1-BA mRNA CTD PMID:31881176 ammonium chloride affects expression ISO RGD:1595867 6480464 Ammonium Chloride affects the expression of RT1-BA mRNA CTD PMID:16483693 antirheumatic drug decreases expression EXP 6480464 Antirheumatic Agents results in decreased expression of HLA-DQA1 mRNA CTD PMID:24449571 arsane affects expression EXP 6480464 Arsenic affects the expression of HLA-DQA1 mRNA CTD PMID:18414638 arsane multiple interactions EXP 6480464 [Arsenic results in increased abundance of Arsenicals] which affects the expression of HLA-DQA1 mRNA CTD PMID:28793237 arsane increases methylation EXP 6480464 Arsenic results in increased methylation of HLA-DQA1 gene CTD PMID:27838757 arsenic atom affects expression EXP 6480464 Arsenic affects the expression of HLA-DQA1 mRNA CTD PMID:18414638 arsenic atom multiple interactions EXP 6480464 [Arsenic results in increased abundance of Arsenicals] which affects the expression of HLA-DQA1 mRNA CTD PMID:28793237 arsenic atom increases methylation EXP 6480464 Arsenic results in increased methylation of HLA-DQA1 gene CTD PMID:27838757 atrazine affects methylation ISO RGD:1595867 6480464 Atrazine affects the methylation of RT1-BA gene CTD PMID:28931070 auranofin increases response to substance EXP 6480464 HLA-DQA1 gene polymorphism results in increased susceptibility to Auranofin CTD PMID:11436868 azathioprine affects response to substance EXP 6480464 HLA-DQA1 gene polymorphism affects the susceptibility to Azathioprine CTD PMID:25217962 benzene decreases expression EXP 6480464 Benzene results in decreased expression of HLA-DQA1 mRNA CTD PMID:16188091 benzo[a]pyrene multiple interactions ISO RGD:1619269 6480464 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of H2-AA mRNA] CTD PMID:22228805 benzo[a]pyrene increases expression ISO RGD:1619269 6480464 Benzo(a)pyrene results in increased expression of H2-AA mRNA CTD PMID:22228805 , PMID:23735875 Benzo[k]fluoranthene increases expression ISO RGD:1619269 6480464 benzo(k)fluoranthene results in increased expression of H2-AA mRNA CTD PMID:26377693 bexarotene multiple interactions ISO RGD:1595867 6480464 [bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-BA mRNA CTD PMID:17630414 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1595867 6480464 Diethylhexyl Phthalate results in decreased expression of RT1-BA mRNA CTD PMID:21318169 bisphenol A decreases expression ISO RGD:1595867 6480464 bisphenol A results in decreased expression of HLA-DQA1 mRNA CTD PMID:25181051 bisphenol A increases expression ISO RGD:1595867 6480464 bisphenol A results in increased expression of RT1-BA mRNA CTD PMID:30816183 buspirone decreases expression ISO RGD:1595867 6480464 Buspirone results in decreased expression of RT1-BA mRNA CTD PMID:24136188 cadmium dichloride decreases methylation ISO RGD:1595867 6480464 Cadmium Chloride results in decreased methylation of RT1-BA promoter CTD PMID:22457795 cadmium dichloride increases expression ISO RGD:1595867 6480464 Cadmium Chloride results in increased expression of RT1-BA mRNA CTD PMID:25993096 cadmium dichloride increases expression ISO RGD:1619269 6480464 Cadmium Chloride results in increased expression of H2-AA mRNA CTD PMID:24982889 calcitriol decreases expression EXP 6480464 Calcitriol results in decreased expression of HLA-DQA1 mRNA CTD PMID:26485663 carbon nanotube affects expression ISO RGD:1619269 6480464 Nanotubes, Carbon affects the expression of H2-AA mRNA, Nanotubes, Carbon analog affects the expression of H2-AA mRNA CTD PMID:25554681 carbon nanotube increases expression ISO RGD:1619269 6480464 Nanotubes, Carbon results in increased expression of H2-AA mRNA CTD PMID:25620056 carbon nanotube decreases expression ISO RGD:1619269 6480464 Nanotubes, Carbon analog results in decreased expression of H2-AA mRNA CTD PMID:25620056 chloroprene decreases expression ISO RGD:1619269 6480464 Chloroprene results in decreased expression of H2-AA mRNA CTD PMID:23125180 copper atom decreases expression ISO RGD:1595867 6480464 Copper results in decreased expression of RT1-BA mRNA CTD PMID:22465980 , PMID:30556269 copper(0) decreases expression ISO RGD:1595867 6480464 Copper results in decreased expression of RT1-BA mRNA CTD PMID:22465980 , PMID:30556269 coumarin increases expression ISO RGD:1595867 6480464 coumarin results in increased expression of RT1-BA mRNA CTD PMID:18480146 DDT decreases methylation ISO RGD:1595867 6480464 DDT results in decreased methylation of RT1-BA gene CTD PMID:30207508 decabromodiphenyl ether increases expression ISO RGD:1595867 6480464 decabromobiphenyl ether results in increased expression of RT1-BA mRNA CTD PMID:23914054 decabromodiphenyl ether decreases expression ISO RGD:1595867 6480464 decabromobiphenyl ether results in decreased expression of RT1-BA mRNA CTD PMID:23640034 dexamethasone increases expression EXP 6480464 Dexamethasone results in increased expression of HLA-DQA1 mRNA, Dexamethasone results in increased expression of HLA-DQA1 protein CTD PMID:12732289 dexamethasone increases expression ISO RGD:1619269 6480464 Dexamethasone results in increased expression of H2-AA mRNA CTD PMID:21041162 dextran sulfate increases expression ISO RGD:1619269 6480464 Dextran Sulfate results in increased expression of H2-AA mRNA CTD PMID:23894361 dichloromethane increases expression ISO RGD:1595867 6480464 Methylene Chloride results in increased expression of RT1-BA mRNA CTD PMID:20955722 diethylstilbestrol increases expression ISO RGD:1619269 6480464 Diethylstilbestrol results in increased expression of H2-AA mRNA CTD PMID:21041162 dioxygen multiple interactions ISO RGD:1619269 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of H2-AA mRNA CTD PMID:30529165 diuron decreases expression ISO RGD:1595867 6480464 Diuron results in decreased expression of RT1-BA mRNA CTD PMID:25152437 doxorubicin decreases expression ISO RGD:1619269 6480464 Doxorubicin results in decreased expression of H2-AA mRNA CTD PMID:17888722 ethylbenzene increases expression ISO RGD:1595867 6480464 ethylbenzene results in increased expression of RT1-BA mRNA CTD PMID:20955722 flutamide decreases expression ISO RGD:1595867 6480464 Flutamide results in decreased expression of RT1-BA mRNA CTD PMID:24136188 fluvastatin affects expression EXP 6480464 fluvastatin affects the expression of HLA-DQA1 mRNA CTD PMID:25811541 gentamycin increases expression ISO RGD:1595867 6480464 Gentamicins results in increased expression of RT1-BA mRNA CTD PMID:22061828 hydrazine decreases expression ISO RGD:1619269 6480464 hydrazine results in decreased expression of H2-AA mRNA CTD PMID:15282401 isoprenaline decreases expression ISO RGD:1619269 6480464 Isoproterenol results in decreased expression of H2-AA mRNA CTD PMID:20003209 lead diacetate increases expression ISO RGD:1619269 6480464 lead acetate results in increased expression of H2-AA mRNA CTD PMID:22609695 lumiracoxib affects response to substance EXP 6480464 HLA-DQA1 gene SNP affects the susceptibility to lumiracoxib CTD PMID:20639878 menadione affects expression ISO RGD:1619269 6480464 Vitamin K 3 affects the expression of HLA-DQA1 mRNA CTD PMID:20829426 mercaptopurine affects response to substance EXP 6480464 HLA-DQA1 gene polymorphism affects the susceptibility to Mercaptopurine CTD PMID:25217962 mercury atom decreases expression EXP 6480464 Mercury results in decreased expression of HLA-DQA1 mRNA CTD PMID:16823088 , PMID:19937285 mercury dichloride increases expression ISO RGD:1595867 6480464 Mercuric Chloride results in increased expression of RT1-BA protein CTD PMID:9536116 mercury(0) decreases expression EXP 6480464 Mercury results in decreased expression of HLA-DQA1 mRNA CTD PMID:16823088 , PMID:19937285 N-(6-acetamidohexyl)acetamide decreases expression ISO RGD:1619269 6480464 hexamethylene bisacetamide results in decreased expression of H2-AA mRNA CTD PMID:26941288 N-nitrosodiethylamine increases expression ISO RGD:1595867 6480464 Diethylnitrosamine results in increased expression of RT1-BA mRNA CTD PMID:19638242 N-nitrosodimethylamine increases expression ISO RGD:1595867 6480464 Dimethylnitrosamine results in increased expression of RT1-BA mRNA CTD PMID:25380136 nimesulide decreases expression ISO RGD:1595867 6480464 nimesulide results in decreased expression of RT1-BA mRNA CTD PMID:24136188 oxaliplatin increases expression ISO RGD:1595867 6480464 oxaliplatin results in increased expression of RT1-BA mRNA CTD PMID:25729387 oxaliplatin multiple interactions ISO RGD:1595867 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of RT1-BA mRNA CTD PMID:25729387 ozone multiple interactions ISO RGD:1619269 6480464 [H2-AB1 gene mutant form co-treated with H2-AA gene mutant form co-treated with H2-EB1 gene mutant form co-treated with H2-EB2 gene mutant form co-treated with H2-EA gene mutant form] inhibits the reaction [Ozone results in increased expression of LTA mRNA] more ... CTD PMID:20032013 ozone decreases expression ISO RGD:1619269 6480464 Ozone results in decreased expression of H2-AA mRNA CTD PMID:12763052 palladium affects response to substance EXP 6480464 HLA-DQA1 gene polymorphism affects the susceptibility to Palladium CTD PMID:8725357 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of HLA-DQA1 mRNA CTD PMID:26690555 phenobarbital affects expression ISO RGD:1619269 6480464 Phenobarbital affects the expression of H2-AA mRNA CTD PMID:23091169 pirinixic acid multiple interactions ISO RGD:1619269 6480464 PPARA protein promotes the reaction [pirinixic acid results in decreased expression of H2-AA mRNA] CTD PMID:20059764 pirinixic acid decreases expression ISO RGD:1619269 6480464 pirinixic acid results in decreased expression of H2-AA mRNA CTD PMID:17426115 more ... propanal decreases expression EXP 6480464 propionaldehyde results in decreased expression of HLA-DQA1 mRNA CTD PMID:26079696 propiconazole decreases expression ISO RGD:1619269 6480464 propiconazole results in decreased expression of H2-AA mRNA CTD PMID:21278054 purine-6-thiol affects response to substance EXP 6480464 HLA-DQA1 gene polymorphism affects the susceptibility to Mercaptopurine CTD PMID:25217962 quercetin increases expression ISO RGD:1619269 6480464 Quercetin results in increased expression of H2-AA mRNA, Quercetin results in increased expression of HLA-DQA1 mRNA CTD PMID:16455785 , PMID:25862958 quercitrin affects expression EXP 6480464 quercitrin affects the expression of HLA-DQA1 mRNA CTD PMID:25193878 rotenone increases expression ISO RGD:1595867 6480464 Rotenone results in increased expression of RT1-BA mRNA CTD PMID:28374803 silver atom decreases expression EXP 6480464 Silver results in decreased expression of HLA-DQA1 mRNA CTD PMID:26551752 silver(0) decreases expression EXP 6480464 Silver results in decreased expression of HLA-DQA1 mRNA CTD PMID:26551752 sodium arsenite increases expression ISO RGD:1619269 6480464 sodium arsenite results in increased expression of H2-AA protein CTD PMID:29044176 sodium dichromate decreases expression ISO RGD:1619269 6480464 sodium bichromate results in decreased expression of H2-AA mRNA CTD PMID:22155349 tamoxifen multiple interactions ISO RGD:1595867 6480464 [bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-BA mRNA CTD PMID:17630414 testosterone enanthate affects expression EXP 6480464 testosterone enanthate affects the expression of HLA-DQA1 mRNA CTD PMID:17440010 tetrachloromethane increases expression ISO RGD:1619269 6480464 Carbon Tetrachloride results in increased expression of H2-AA mRNA CTD PMID:27339419 titanium dioxide decreases expression ISO RGD:1619269 6480464 titanium dioxide results in decreased expression of H2-AA mRNA CTD PMID:27760801 titanium dioxide increases expression ISO RGD:1619269 6480464 titanium dioxide results in increased expression of H2-AA mRNA CTD PMID:23557971 toluene 2,4-diisocyanate decreases expression ISO RGD:1619269 6480464 Toluene 2, 4-Diisocyanate results in decreased expression of H2-AA mRNA CTD PMID:21404309 topotecan increases expression ISO RGD:1595867 6480464 Topotecan results in increased expression of RT1-BA mRNA CTD PMID:25729387 topotecan multiple interactions ISO RGD:1595867 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of RT1-BA mRNA CTD PMID:25729387 Tributyltin oxide increases expression ISO RGD:1619269 6480464 bis(tri-n-butyltin)oxide results in increased expression of H2-AA mRNA CTD PMID:18958704 trichloroethene increases expression ISO RGD:1595867 6480464 Trichloroethylene results in increased expression of RT1-BA mRNA CTD PMID:20955722 tungsten increases expression ISO RGD:1619269 6480464 Tungsten results in increased expression of H2-AA mRNA CTD PMID:30912803 valproic acid affects expression ISO RGD:1619269 6480464 Valproic Acid affects the expression of H2-AA mRNA CTD PMID:17963808 vancomycin decreases expression ISO RGD:1619269 6480464 Vancomycin results in decreased expression of H2-AA mRNA CTD PMID:18930951 vinclozolin affects expression ISO RGD:1595867 6480464 vinclozolin affects the expression of RT1-BA mRNA CTD PMID:19015723 vorinostat increases expression ISO RGD:1619269 6480464 vorinostat results in increased expression of H2-AA mRNA CTD PMID:26941288
Biological Process adaptive immune response IEA UniProtKB-KW:KW-1064 2290271 UniProt GO_REF:0000043 antigen processing and presentation IEA InterPro:IPR001003 , InterPro:IPR014745 2290271 InterPro GO_REF:0000002 antigen processing and presentation of exogenous peptide antigen via MHC class II TAS 2290271 Reactome Reactome:R-HSA-2132295 immune response NAS 2290271 (PMID:3584986), (PMID:6415485) UniProtKB PMID:3584986 , PMID:6415485 immune response IEA InterPro:IPR001003 , InterPro:IPR014745 2290271 InterPro GO_REF:0000002 interferon-gamma-mediated signaling pathway TAS 2290271 Reactome Reactome:R-HSA-877300 T cell receptor signaling pathway TAS 2290271 Reactome Reactome:R-HSA-202403 Cellular Component clathrin-coated endocytic vesicle membrane TAS 2290271 Reactome Reactome:R-HSA-2130486, Reactome:R-HSA-2130725 endocytic vesicle membrane TAS 2290271 Reactome Reactome:R-HSA-2130486, Reactome:R-HSA-2213235 endosome membrane IEA UniProtKB-SubCell:SL-0100 2290271 UniProt GO_REF:0000044 ER to Golgi transport vesicle membrane TAS 2290271 Reactome Reactome:R-HSA-2130731, Reactome:R-HSA-2213243 Golgi membrane TAS 2290271 Reactome Reactome:R-HSA-2130393, Reactome:R-HSA-2213243 integral component of lumenal side of endoplasmic reticulum membrane TAS 2290271 Reactome Reactome:R-HSA-2130478 more ... integral component of membrane IEA UniProtKB-KW:KW-0812 2290271 UniProt GO_REF:0000043 integral component of plasma membrane NAS 2290271 (PMID:3584986), (PMID:6415485) UniProtKB PMID:3584986 , PMID:6415485 lysosomal membrane TAS 2290271 Reactome Reactome:R-HSA-2130336 more ... membrane HDA 2290271 (PMID:19946888) UniProtKB PMID:19946888 MHC class II protein complex ISS UniProtKB:P20036 2290271 (PMID:20356827) UniProtKB PMID:20356827 MHC class II protein complex IEA InterPro:IPR001003 , InterPro:IPR014745 2290271 InterPro GO_REF:0000002 plasma membrane TAS 2290271 Reactome Reactome:R-HSA-1031716 more ... trans-Golgi network membrane TAS 2290271 Reactome Reactome:R-HSA-2130378 more ... transport vesicle membrane TAS 2290271 Reactome Reactome:R-HSA-2130378, Reactome:R-HSA-2130500 Molecular Function metal ion binding IEA UniProtKB-KW:KW-0479 2290271 UniProt GO_REF:0000043 MHC class II receptor activity TAS 2290271 (PMID:2300572) UniProtKB PMID:2300572 MHC class II receptor activity NAS 2290271 (PMID:3584986), (PMID:6415485) UniProtKB PMID:3584986 , PMID:6415485 peptide antigen binding ISS UniProtKB:P20036 2290271 (PMID:20356827) UniProtKB PMID:20356827 protein binding IPI UniProtKB:P01920 2290271 (PMID:14769912), (PMID:17629515), (PMID:29997244) IntAct PMID:14769912 more ...
Human Phenotype Abnormality of the thyroid gland susceptibility IAGP 5147646 DNA:polymorphisms:cds:HLA-DQA1*03, HLA-DQ1*0401 RGD Anti-La/SSA antibody positivity susceptibility IAGP 5147809 DNA:polymorphisms:cds:HLA-DQA1*0101, HLA-DQA1*0501 RGD Aortic regurgitation IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Arthritis IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Asthma IAGP 5147813 DNA:polymorphism:cds:HLA-DQA1*0201 RGD Autoimmune antibody positivity susceptibility IAGP 5147646 DNA:polymorphisms:cds:HLA-DQA1*03, HLA-DQ1*0401 RGD Back pain severity IAGP 5147611 DNA:polymorphism:cds:HLA-DQA1*0401 RGD Cataplexy susceptibility IAGP 5147861 DNA:polymorphisms:cds:multiple RGD Chorea IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD EMG abnormality susceptibility IAGP 5147612 DNA:polymorphisms: :HLA-DQA1*0101/2, HLA-DQA1*0501 (human) RGD Erythema IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Fatigable weakness IAGP 5147855 DNA:polymorphisms, haplotype:cds:HLA-DQA!*0501, HLA-DQA1*0301 RGD Increased circulating total IgE level IAGP 5147865 associated with Cystic Fibrosis, DNA:polymorphisms, haplotype:cds:HLA-DQA1*0201 RGD Increased circulating total IgE level susceptibility IAGP 5147798 DNA:polymorphisms:cds:HLA-DQA1*0201, HLA-DQA1*0302 RGD Lacunar stroke susceptibility IAGP 5147807 DNA:polymorphisms:cds:HLA-DQA1*0103, HLA-DQA1*0301 RGD Lymphoma IAGP 5147794 associated with Helicobacter Infections, DNA:polymorphism: :HLA-DQA1*0103 RGD Mitral regurgitation IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Myocarditis IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Myositis IAGP 5147629 DNA:polymorphism, haplotype:cds:HLA-DQA1*05 RGD Myositis susceptibility IAGP 5147793 ; 5147869 DNA:polymorphisms:multiple RGD Narcolepsy susceptibility IAGP 5147861 DNA:polymorphisms:cds:multiple RGD Nasal obstruction susceptibility IAGP 5147798 DNA:polymorphisms:cds:HLA-DQA1*0201, HLA-DQA1*0302 RGD Nasal polyposis IAGP 5147813 associated with intrinsic asthma, DNA:polymorphism:cds:HLA-DQA1*0201 RGD Psoriasiform dermatitis susceptibility IAGP 5147797 DNA:polymorphisms:cds:HLA-DQA1*0104, HLA-DQA1*0201, HLA-DQA1*0501 RGD Purpura susceptibility IAGP 5147830 DNA:polymorphisms:cds:HLA-DQA1*0301, HLA-DQA1*0302 RGD Rhinorrhea susceptibility IAGP 5147798 DNA:polymorphisms:cds:HLA-DQA1*0201, HLA-DQA1*0302 RGD Sacroiliac arthritis severity IAGP 5147611 DNA:polymorphism:cds:HLA-DQA1*0401 RGD Subcutaneous nodule IAGP 5147792 DNA:polymorphisms, haplotypes:multiple RGD Type I diabetes mellitus susceptibility IAGP 5147565 DNA:polymorphisms:cds:HLA-DQA1*01, HLA-DQA1*03 RGD
Gene-Chemical Interaction Annotations